2002
DOI: 10.1111/j.2042-7166.2002.tb03405.x
|View full text |Cite
|
Sign up to set email alerts
|

Assalix® for chronic low back pain and arthralgia: Interim analysis of a post‐marketing surveillance study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2013
2013
2013
2013

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…(Glinko, ). Severe adverse events were also not observed in patients treated with willow bark extract, neither in 5 clinical studies over up to 6 weeks (Vlachojannis et al ., ), nor in 3 surveys over 8 weeks including a total of 5871 patients (Werner and Scheithe, , Zenner‐Weber, , Müller‐Faßbender et al ., ) nor in a recently published survey over 6 months including 436 patients (Uehleke et al ., ). The overall adverse event rate during treatment with willow bark extract for chronic back pain, fibromyalgia and/or osteoarthritis was below 3%.…”
mentioning
confidence: 99%
“…(Glinko, ). Severe adverse events were also not observed in patients treated with willow bark extract, neither in 5 clinical studies over up to 6 weeks (Vlachojannis et al ., ), nor in 3 surveys over 8 weeks including a total of 5871 patients (Werner and Scheithe, , Zenner‐Weber, , Müller‐Faßbender et al ., ) nor in a recently published survey over 6 months including 436 patients (Uehleke et al ., ). The overall adverse event rate during treatment with willow bark extract for chronic back pain, fibromyalgia and/or osteoarthritis was below 3%.…”
mentioning
confidence: 99%